Cipher Pharmaceuticals Inc.

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Cipher Pharmaceuticals Inc. Fiscal 2020 Fourth Quarter Results Conference Call. At this time, all participants are in a listen-only mode. Following today's presentation, instructions will be given for the question and answer session. If anyone needs assistance at any time during this call, you may press star followed by the zero on your push-button phone. As a reminder, this conference is being recorded today, Friday, March 19, 2021. On behalf of the speakers that follow, listeners are cautioned that today's presentation and the responses to questions may contain forward-looking statements within the meaning of the safe harbor provisions of the Canadian Provincial Securities Laws. Forward-looking statements involve risks and uncertainties, and under-reliance should not be placed on such statements. Certain material factors or assumptions are implied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. For additional information about factors that could cause results to vary, please refer to the risks identified in the company's annual information form and on other filings with Canadian regulatory authorities. Except as required by Canadian securities laws, the company does not undertake to update any forward-looking statements. Such statements speak only as of the date made.

Hi, everybody. This is Rizwan Chaudhry, and you are listening to the Field Finish podcast, sponsored by Abijek, the show that shares expertise in all aspects of injectables, vaccines, and aseptic field finish. Season one is offering 10 episodes focused on topics including facility design, regulatory, quality, supply chain management, and ARVR, to name just a few. And today I'm delighted to be joined by Parish Gallagher, an independent bioprocess consultant, and we are going to be talking about the current state and trends impacting field finish from formulation through to commercialization. So Parish, first of all, it's lovely to meet you. How are you? Very well, thank you. Well, Parish, before we start talking about the impact of field finish on the trends, would you mind giving the listeners a quick overview of your role and your business?

So I've been in bioprocessing for over 40 years in four different drug companies. I helped bring two drugs to market, built a number of stainless steel facilities and single-use facilities. And I started my own company 20 years ago in single-use manufacturing and sold that to GE Healthcare a couple of years ago. Right now, I'm an independent bioprocess consultant.